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Introduction: The clinical features of Alzheimer’s disease (AD) overlap with a number of other dementias and
conclusive diagnosis is only achieved at autopsy. Accurate in-life diagnosis requires finding biomarkers suitable
for early diagnosis, as well as for discrimination from other types of dementia. Mounting evidence suggests that
AD-dependent processes may also affect peripheral cells. We previously reported that calmodulin (CaM) signaling
is impaired in AD lymphoblasts. Here, we address the issue as to whether the assessment of CaM levels in
peripheral cells could serve as a diagnostic biomarker.
Methods: A total of 165 subjects were enrolled in the study, including 56 AD patients, 15 patients with mild
cognitive impairment, 7 with frontotemporal dementia associated with progranulin mutations, 4 with dementia
with Lewy bodies, 20 patients with Parkinson’s disease, 10 with amyotrophic lateral sclerosis, 5 with progressive
supranuclear palsy, and 48 cognitively normal individuals. CaM levels were then analyzed in lymphoblasts,
peripheral blood mononuclear cells and plasma. Receiver operating characteristic (ROC) curve analyses were
employed to evaluate the diagnostic performance of CaM content in identifying AD patients.
Results: Compared with control individuals, CaM levels were significantly increased in AD cells, but not in the other
neurodegenerative disorders. CaM levels differentiated AD from control with a sensitivity of 0.89 and a specificity of
0.82 and were not dependent on disease severity or age. MCI patients also showed higher levels of the protein.
Conclusions: CaM levels could be considered a peripheral biomarker for AD in its early stage and help to discriminate
from other types of dementia.Introduction
Alzheimer’s disease (AD) is the most common form of
dementia in older people. The diagnosis of AD is made
following clinical criteria and only postmortem autopsy
can really confirm the disease [1,2]. AD diagnosis is time
consuming and requires a combination of clinical assess-
ment, psychological testing, imaging and exclusion of other
neurological disorders. The availability of reliable minim-
ally invasive biomarkers for AD progression, and especially
for incipient AD, would be of great interest for an early
diagnosis and hopefully to slow disease progression.* Correspondence: amrequero@cib.csic.es
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stated.AD pathogenesis is not completely understood and
diagnosis often occurs after significant neuronal loss and
pathology have occurred. However, a variety of postmor-
tem evidence suggests that the pathological hallmarks of
AD begin to occur early in an individual’s life. Both
disease-specific genetics and environmental factors affect
cellular pathways before the clinical onset. Alterations in
cellular response to these stressors are not restricted to
neurons, representing a systemic pathophysiological pro-
cess [3-7]. For example, the accumulation of senile plaques
in the central nervous system formed by amyloid-beta
deposits is the main hallmark of the disease [8], but is also
present in the periphery and can be detected in blood [9].
Moreover, systemic changes at the immunological level
have been reported to be associated with increased inflam-
mation in the brain [10,11], indicating that the hemato-
poietic system and the central nervous system are affected
similarly by AD-dependent processes. Blood cells, easilyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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specific signature molecules that eventually could serve as
biomarkers for AD. A blood-based biomarker would be
ideal since venous puncture is a widely accepted proced-
ure with no risk and low cost for sample collection.
Work carried out in our laboratory in the past few
years aimed at investigating whether changes in cell
cycle-related events could be important in the neurode-
generative process, and to demonstrate the usefulness of
peripheral cells from AD patients to determine AD
pathogenesis [7,12]. We reported a functional relationship
between Ca2+/calmodulin (CaM) and the main signaling
pathways controlling cell survival or death depending upon
growth factor availability in either Epstein–Barr virus-
immortalized lymphocytes or freshly isolated lymphocytes
[13-15]. These features were considered peripheral signs
of the disease, because current evidence relates the pro-
cess of neuronal apoptosis occurring in AD to the aber-
rant re-entry of differentiated neurons into the cell cycle
[16-18]. Moreover, we detected significantly increased
levels of CaM in AD lymphoblasts [19].
The present work was undertaken to elucidate whether
higher CaM content is a characteristic feature of AD or
whether it may occur in other neurodegenerative disor-
ders. To this end, we determined CaM levels in lympho-
blastoid cell lines and peripheral blood mononuclear cells
(PBMCs) from nondemented individuals, and from sub-
jects with mild, moderate or severe AD. A small group of
mild cognitive impairment (MCI) individuals has been
included. MCI is a prodromal phase of AD characterized
by the onset of the earliest cognitive symptoms (typically
deficits in episodic memory) that do not meet the criteria
for dementia [20]. The time and sequence of changes in
AD are considered important factors for improving early
diagnosis and treatment [21,22]. In addition, we included
samples from frontotemporal dementia (FTD) patients,
carriers of the splicing mutation c.709-1G > A in the
progranulin (PGRN) gene [23], patients with dementia
with Lewy bodies (DLB), as well as patients suffering from
Parkinson’s disease (PD), amyotrophic lateral sclerosis
(ALS) and progressive supranuclear palsy (PSP) as other
neurodegenerative disorders. We found that assessing the
CaM content in lymphocytes could help to discriminate
between AD patients and non-AD individuals including
patients with other dementias or neurodegenerative disor-
ders, and therefore the CaM content of peripheral cells
may become a potential biomarker for AD.
Methods
Subjects
Healthy controls and patients enrolled in the study were
recruited from Hospital Doce de Octubre, Madrid, Spain.
Individuals carrying a loss-of-function PGRN mutation,
c.709-1G >A [23], suffering from FTD were recruited inHospital Donostia, San Sebastián, Spain. The clinical diag-
nosis of probable AD was based on the criteria of the
National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association [1] and on the Diagnostic
and Statistical Manual of Mental Disorders IV criteria,
and diagnosis required evidence of cognitive decline
(neuropsychological test battery, clinical mental examin-
ation) as well as evidence of impairment in social or occu-
pational function. The Mini-Mental State Examination
was used to assess cognitive function [24]. Classification
of mild, moderate and severe degrees of AD was per-
formed using Diagnostic and Statistical Manual of Mental
Disorders III-R criteria. MCI was diagnosed using consen-
sus criteria of the International Working Group on MCI
[25]. The diagnosis of FTD was performed by applying
consensus criteria as published elsewhere [26]. These
individuals carry a loss-of-function PGRN mutation,
c.709-1G >A, described previously [23]. Established crite-
ria were applied for the diagnosis of DLB [27], ALS [28],
probable PD [29] and PSP [30]. The control group was
formed by individuals – in general, family members of the
patients – with no signs of neurological disease or cogni-
tive decline.
Blood collection
This study was approved by the Ethic Committee of
Clinical Investigation of Hospital 12 de Octubre and
Hospital Donostia and by the Spanish Council of Higher
Research Institutional Review Board. Informed consent
from all subjects was obtained prior to their participation.
Sampling protocols were similar in both clinical centers.
Blood samples (approximately 8 ml) were obtained through
antecubital vein puncture in ethylenediamine tetraacetic
acid-treated VacutainerW tubes (BD, Madrid, Spain). Plasma
was obtained after centrifugation (2,000 rpm, 10 minutes),
apportioned into 500 μl aliquots in polypropylene tubes,
and stored at −80°C.
Isolation of peripheral blood mononuclear cells and
establishment of lymphoblastoid cell lines
PBMCs were isolated on Lymphoprep™ density-gradient
centrifugation according to the instructions of the manu-
facturer (Axix-Shield Po CAS, Oslo, Norway). Cells were
washed twice with phosphate-buffered saline, counted,
and resuspended at the desired concentration.
Establishment of lymphoblastoid cell lines was per-
formed in our laboratory by infecting peripheral blood
lymphocytes with the Epstein–Barr virus as described
previously [31]. Cells were grown in suspension in T
flasks in an upright position, in approximately 10 ml RPMI
1640 (Gibco, BRL San Francisco, CA, USA) medium that
contained 2 mML-glutamine, 100 μg/ml penicillin/strepto-
mycin and, unless otherwise stated, 10% (v/v) fetal bovine
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oxide incubator at 37°C. Fluid was routinely changed every
2 days by removing the medium above the settled cells and
replacing it with an equal volume of fresh medium.
Cell extracts
To prepare cell extracts, cells were harvested, washed in
phosphate-buffered saline and then lysed in ice-cold lysis
buffer (50 mM Tris pH 7.4, 150 mM NaCl, 50 mM NaF,
1% Nonidet P-40) containing 1 mM sodium orthovana-
date, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium
pyrophosphate and protease inhibitor Complete Mini
Mixture (Roche, Mannhein, Germany). When preparing
cell extracts from PBMCs, cells were pretreated with red
blood cell lysis buffer (154 mM NH4Cl, 14 mM NaHCO3,
0.1 mM ethylenediamine tetraacetic acid) for 5 minutes, to
remove red blood cells from the PBMC pellet. The protein
content of the extracts was determined by the BCA protein
assay kit (Thermo Scientific Alcobendas, Madrid, Spain).
Western blot analysis
Protein (40 μg) from cell extracts were fractionated on a
SDS polyacrylamide gel and transferred to a polyvinyli-
dene fluoride membrane, which was then blocked with 5%
bovine serum albumin and incubated overnight at 4°C,
with primary antibodies at the following dilutions: 1:500
anti-CaM (FL-149; Santa Cruz Biotechnologies, Santa
Cruz, CA, USA) and 1:5,000 anti-β-actin (Sigma Aldrich,
Alcobendas, Madrid, Spain). Signals from the primary anti-
bodies were amplified using species-specific antisera conju-
gated with horseradish peroxidase (Bio-Rad Richmond,
CA, USA) and were detected with a chemiluminescent
substrate detection system (ECL; Amersham, Uppsala,
Sweden). The specificity of the antibodies used in this work
was checked by omitting the primary antibodies in the in-
cubation medium. Protein band densities were quantified
using Image J software (NIH, Bethesda, MD, USA) after
scanning the images with a GS-800 densitometer from
Bio-Rad. To compare the results between experiments, all
results were normalized by a standard sample included in
every western blot. CaM levels of each individual were
analyzed at least in two different experiments.
Mass spectrometry analysis of calmodulin
For CaM identification, 40 μg protein from cell lysates
were loaded in SDS-PAGE. The gel was then stained
with SYPROWRuby (Invitrogen, Carlsbad, CA, USA),
and the band of interest was cut, destained and washed,
and after dithiothreitol reduction and iodoacetamide
alkylation was digested with trypsin. Peptides were
extracted from the gel and then analyzed in an
LTQ Orbitrap Velos (Thermo-Scientific, Alcobendas,
Madrid, Spain) coupled to a nanoEasy HPLC (Proxeon,
Odense, Denmark). Peptides were first trapped onto aC18-A1 ASY-Column 2 cm precolumn (Thermo-Scientific,
Alcobendas, Madrid, Spain), and then eluted onto a
Biosphere C18 column (C18, inner diameter 75 μm, 15 cm
long, 3 μm particle size; NanoSeparations, Nieuwkoop,
The Netherlands) and separated using a 80-minute gradi-
ent from 3 to 35% Buffer B (Buffer A, 0.1% formic acid/2%
acetonitrile; Buffer B, 0.1% formic acid in acetonitrile) at a
flow rate of 250 nl/minute. Mass spectra were acquired in
the positive ion mode and in a data-dependent manner
selecting the 15 most intense ions for fragmentation using
collision-induced dissociation. Full scan spectra (m/z 300
to 1,600) were acquired in the Orbitrap with a target value
of 1,000,000 at a resolution of 30,000 (at m/z 400) and
MS2 spectra were acquired in the linear ion trap with a tar-
get value of 10,000 and normalized collision energy of
38%. Precursor ion charge state screening and mono-
isotopic precursor selection were enabled. Singly
charged ions and unassigned charge states were
rejected. Dynamic exclusion was enabled with a re-
peat count of 1 and exclusion duration of 30 seconds.
Acquired spectra were searched against the human
SwissProt database (091813) using the Sequest search en-
gine through PD1.4 (Thermo-Scientific, Alcobendas,
Madrid, Spain). As for the search parameters, the precursor
and fragment mass tolerance were set to 10 ppm and
0.8 Da, respectively. Carbamidomethylation of cysteines
was set as a fixed modification, and oxidation of methio-
nines was set as a dynamic modification. Two missed cleav-
ages were allowed. Identified peptides were validated using
the Percolator algorithm with a q-value threshold of 0.01.Enzyme-linked immunosorbent assay analysis
CaM levels were detected in plasma using a Human
Calmodulin Elisa kit from MyBiosource (San Diego, CA,
USA) according to the manufacturer’s instructions. Then
50 μl plasma were added in duplicate to the microtiter
wells. Sensitivity of the assay was 1.0 pg/ml. The coeffi-
cient of variation in the same lot was <9%, and in a
different lot was <10%. Spike recovery was 94 to 103%.
Linearity was in the following ranges: 1:2 (96 to 101%), 1:4
(93 to 107%), 1:8 (92 to 100%), and 1:16 (96 to 108%).Statistical analysis
Normality was checked with the Kolmogorov–Smirnov
test with a Dallal Wilkinson–Lilliefor p value. p >0.10
was observed, indicating that the data were consistent
with a Gaussian distribution. Parametric tests were there-
fore used in the statistical analysis.
Statistical significance was estimated by one-way ana-
lysis of variance followed by the Tukey’s test for multiple
comparisons. When appropriate, two-way analysis of
variance or Student’s t test was performed. Differences
were considered significant at p <0.05.
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the sensitivity against 1 – specificity for different cutoff
values. Areas under the ROC curves were calculated. The
best cutoff value to distinguish AD patients from controls
or other diseases was selected to achieve a sensitivity and a
specificity >80%, as described previously [32]. Sensitivity,
specificity, and accuracy were calculated for that certain
cutoff point. Statistical analyses were performed using
GraphPad Prism 6.0 for Mac (San Diego, CA, USA).
Results
Calmodulin content in Epstein–Barr virus-immortalized
lymphocytes from controls and individuals suffering from
neurodegenerative disorders
The clinical characterization and demographic data of
the study groups of controls and AD, FTD, DLB, PD, ALS
and PSP patients are summarized in the upper part of
Table 1. Lymphoblastoid cell lines were generated by
transformation with the Epstein–Barr virus, and the CaMTable 1 Summary of the study population
Number Age Gender
Mean Age range Male Female
Lymphoblasts
HC 33 64 ± 13 (31 to 83) 12 21
MCI 8 73 ± 6 (62 to 82) 4 4
AD
Total 35 75 ± 7 (59 to 90) 16 19
Mild 18 76 ± 6 (60 to 83) 8 10
Moderate 10 76 ± 7 (59 to 84) 4 6
Severe 7 73 ± 10 (60 to 90) 4 3
FTD 7 64 ± 6 (54 to 70) 0 7
DLB 4 73 ± 15 (58 to 91) 3 1
PD 20 69 ± 10 (49 to 83) 14 6
ALS 10 63 ± 10 (47 to 79) 6 4
PSP 5 79 ± 6 (72 to 85) 1 4
Peripheral blood
mononuclear cells
HC 15 68 ± 8.3 (57 to 81) 4 11
MCI 7 68 ± 7.6 (55 to 76) 4 3
AD
Total 21 77 ± 9 (58 to 88) 9 12
Mild 10 73 ± 9 (60 to 85) 5 5
Moderate 10 79 ± 8 (58 to 86) 4 6
Severe 1 88 88 0 1
Values expressed as mean ± standard deviation. HC, healthy control
individuals, no sign of neurological disease; MCI, patients with a diagnosis of
mild cognitive impairment; AD, patients with a diagnosis of probable
Alzheimer’s disease; FTD, frontotemporal dementia individuals carrying a loss-
of-function PGRN mutation; DLB, patients diagnosed for dementia with Lewy
bodies; PD, patients with probable Parkinson’s disease; ALS, patients with a
diagnosis of amyotrophic lateral sclerosis; PSP, patients diagnosed of progres-
sive supranuclear palsy.content was determined by western blotting. To confirm
the identity of the immunosignal detected by western blot-
ting as CaM, the band was analyzed by mass spectrometry
as described in Methods. Five peptides were identified
with high confidence (Additional file 1), confirming that
the band detected by western blotting indeed corres-
ponded with CaM.
The cellular levels of CaM in lymphoblasts from individ-
uals of the above study groups are presented in Figure 1.
We found that CaM levels were significantly higher in AD
subjects than in controls. In contrast, we did not find differ-
ences between cells from controls or patients affected by
other forms of dementia, such as DLB, or FTD associated
with a loss-of-function PGRN mutation (c-709-1G >A), as
well as cells from patients suffering from other neurodegen-
erative disorders such as PD, ALS or PSP.
To evaluate the diagnostic performance of CaM content
as an AD biomarker, ROC curves were generated (Figure 2).
AD was compared with control, FTD and PD patients. The
areas under the ROC curves were 0.945 (p <0.0001) for the
classification control/AD, and 0.979 (p <0.0001) and 0.944
(p <0.0001) for AD/FTD and AD/PD respectively. Sensitiv-
ity, specificity and accuracy were calculated for the opti-
mal cutoff point to distinguish AD patients and were the
following: 0.886/0.818/0.853 for control/AD; 0.886/1/
0.905 for AD/FTD; and 0.886/0.85/0.873 for AD/PD.
Calmodulin content, age, gender and Alzheimer’s disease
severity
To better characterize the difference in CaM content
of control and AD lymphoblasts, we studied whether
this feature correlated with parameters associated
with AD such as age or disease severity. AD patients
were classified in three groups according to Diagnos-
tic and Statistical Manual of Mental Disorders III-R
criteria: mild (Mini-Mental State Examination score
between 18 and 24), moderate (Mini-Mental State
Examination score between 10 and 18), and severe
(Mini-Mental State Examination score <10). A group
of patients with amnesic MCI, which could constitute
a prodromal stage of AD because these patients have
a high risk of progression to AD [33], was also included.
CaM content in both control and AD patients appears to
be independent of age, as the difference between the
slopes was not significant (p = 0.80) (Figure 3A). Likewise,
the effect of gender was considered not significant
(p = 0.70) (Figure 3B). The CaM content in AD pa-
tients was also independent of disease severity as there
were no differences between lymphoblasts from early or
advanced disease patients (Figure 3C). CaM levels were
increased even in the MCI group, although to a lesser
extent than in the AD patients (p = 0.06 MCI relative to
control individuals, p = 0.26 when comparing MCI and
mild AD patients).
Figure 1 Calmodulin levels in lymphoblasts from control, Alzheimer’s disease and other neurodegenerative disease patients.
Immortalized lymphocytes from all of the individuals listed in the upper part of Table 1 were seeded at an initial density of 1 × 106/ml and
cultured for 24 hours in RPMI medium containing 10% fetal bovine serum. At that time, cells were harvested and calmodulin (CaM) was detected
by immunoblotting. A representative experiment is shown. Band intensity was measured and normalized by that of β-actin. To compare the re-
sults between experiments, the same standard sample (ST) was included in every western blot assay, and all the values were referred to ST CaM
levels. At least two different experiments were performed with each individual. Box plots represent the CaM content in lymphoblasts from healthy
and neurodegenerative disease patients. (**p <0.0001, significantly different from control and the other neurodegenerative diseases). C, control;
AD, Alzheimer’s disease; FTD, frontotemporal dementia; DLB, dementia with Lewy bodies; PD, Parkinson’s disease; ALS, amyotrophic lateral
sclerosis; PSP, progressive supranuclear palsy.
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Alzheimer’s disease subjects
Considering that immortalized lymphocytes are prolifer-
ating cells and that CaM has long been implicated in cell
cycle regulation [34,35], we were interested in verifying
whether differences in CaM levels are also evident bet-
ween freshly isolated quiescent PBMCs from control and
AD patients. Moreover, PBMCs, rather than immortal-
ized lymphocytes, are considered convenient material
for molecular diagnosis in clinical practice. For these
experiments, we collected samples from 15 control
individuals, seven MCI patients and 21 AD patients
(see Table 1, lower part). Approximately 5 × 106 cells
derived from control or AD individuals were taken to
prepare cell extracts. Figure 4 shows the results of
the densitometric analyses of the corresponding im-
munoblots, revealing higher CaM content in quiescent
mononuclear cells from MCI and AD patients when
compared with control cells, thus indicating that the
regulation of CaM content is not affected by the viral
transformation.Analysis of calmodulin content in plasma by enzyme-
linked immunosorbent assay
Considering the need for a suitable assay for diagnostic
purposes, easy to perform in already existing clinical
infrastructures for analyses of blood, we were interested
in evaluating whether quantitatively determined CaM
levels in plasma by enzyme-linked immunosorbent assay
would also serve to identify AD patients. A commercially
available CaM enzyme-linked immunoassay was used for
these experiments (MyBiosource, San Diego, CA, USA).
Figure 5 shows that in AD patients the circulating CaM
levels tended to be higher than in the control group
(median (interquartile interval) 321 (315 to 464) vs. 629
(485to 682); P = 0.09), suggesting that measurement of
CaM in plasma could help in AD diagnosis. Further
work is needed to replicate this finding in larger and
independent populations of patients.
Discussion
Current therapies and treatments for AD are only symp-
tomatic and the disease remains relentlessly progressive.
Figure 2 Receiver operating characteristic curve analysis
comparing Alzheimer’s disease patients and control,
frontotemporal dementia or Parkinson’s disease patients.
Receiver operating characteristic (ROC) curve analysis of
differentiation between Alzheimer’s disease (AD) patients and
healthy controls, between AD and frontotemporal dementia (FTD)
patients, and between AD and Parkinson’s disease (PD) patients. The
area under the ROC curve (AUC) was 0.945 for AD versus control,
0.979 for AD versus FTD, and 0.944 for AD versus PD.
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AD and to design molecular diagnostics and improved
pharmacotherapies is vitally important to the healthcare
system. The aim of the present work was to evaluate
whether the content of CaM in easily accessible, periph-
eral cells could support the clinical diagnosis and discrim-
inate AD from other causes of dementia or even between
different stages of the disorder.
We previously reported increased CaM content in
lymphoblasts from AD patients, as a consequence of
impaired proteasomal degradation of the protein [19].
The higher CaM content was associated with impaired
cell survival/death mechanisms [15,36]. Since cell cycle
dysfunction seems to be a convergent point in neurode-
generative diseases [37], it was interesting to determine
whether the control failure of CaM levels was commonly
involved in neurodegenerative processes or, otherwise,
was a disease-specific marker.
We first checked whether freshly isolated lymphocytes
from AD patients also show increased levels of CaM as
AD lymphoblasts do [19]. Our results indicate that the
regulation of CaM content is not affected by the viral
transformation, because higher levels of CaM were
indeed found in PBMCs from AD patients than in con-
trol cells. This observation highlights the usefulness ofEpstein–Barr virus-transformed lymphocytes as an ex-
perimental model.
Our results indicate that increased CaM content is a
distinct feature of AD, since it was not observed in cells
derived from patients with FTD, carriers of the PGRNmu-
tation c.709-1G >A, DLB, PD, ALS or PSP even consider-
ing that cell cycle disturbances had been also described in
cells from patients of FTD with PGRN mutations [38] and
in other neurodegenerative diseases [37]. What seems to
be unique for AD is the cell sensitivity to CaM-mediated
cell survival control, secondary to increased levels of CaM.
Interestingly, no alteration in CaM levels was found in
DLB, despite the fact that this dementia shares clinical
and pathological characteristics with AD [39].
The changes in CaM content found in AD lympho-
cytes did not correlate with disease severity, suggesting
that this is an early manifestation of the disease. This
observation is in agreement with cell cycle theory, which
states that cell cycle-related event-induced neurode-
generation is not the result of accumulated loss of
neurons but rather an early feature in the instigation
of the disease [40]. This lack of correlation would
also suggest that the cellular CaM content is a trait
disease marker, not reflecting the disease status. Ac-
cordingly, we have also detected increased levels of
CaM in MCI individuals, suggesting the potential of
this variable in differentiating MCI and asymptomatic
individuals.
ROC curve analyses indicate that the CaM content in
peripheral cells is specific and sensitive enough for AD
diagnosis. For the control/AD classification, the area
under the ROC curve was 0.945 (95% confidence inter-
val 0.896, 0.994) with positive or negative predicted
values of 89% and 88% respectively. The overall diagnostic
accuracy was 0.853, similar to currently accepted cere-
brospinal fluid biomarkers (tau, phospho-tau amyloid-beta
1–42) [41]. In addition, determination of the CaM content
in peripheral cells also has the potential of discriminating
AD patients from subjects affected by other forms of
dementia as well as from other neurodegenerative dis-
eases. Taken together, our results add further support to
the usefulness of peripheral lymphocytes for the search of
convenient biomarkers for AD [42-44].
Interestingly, a trend towards higher plasma circulat-
ing levels of CaM in AD subjects versus nondemented
individuals was detected by enzyme-linked immunosorb-
ent assay, a more convenient assay in clinical practice.
However, further work is needed with a larger number
of control and patients affected by AD and other neuro-
degenerative disorders.
AD pathogenesis is very complex. According to the
cell cycle hypothesis, a dysfunction in the G1/S check-
point could play a role in instigation of the disease
[5,45,46]. We previously reported the existence of a
Figure 3 Influence of age, gender and disease severity on calmodulin levels. (A) Scatter plot of calmodulin (CaM) levels versus age in
Alzheimer’s disease (AD) patients and controls. Correlation lines related to control and AD distributions are indicated. (B) Box plot of CaM levels in
male (M) and female (F) controls and AD patients. (**p <0.0001, significantly different from both male and female controls). (C) Box plot of CaM
levels of control, mild cognitive impairment (MCI) patients and AD patients classified within severity segments, as described in the upper part of
Table 1. (**p < 0.0001, significantly different from control).
Esteras et al. Alzheimer's Research & Therapy 2013, 5:55 Page 7 of 10
http://alzres.com/content/5/6/55molecular link between decreased levels of the CDK
inhibitor p27, and increased phosphorylation of pRb
protein and proliferation of AD lymphoblasts [12]. On
the other hand, the CaM content appears to regulate the
rate of p27 degradation in AD cells through a phos-
phoinositide-3 kinase/Akt-dependent mechanism [15].
Moreover, higher levels of CaM also correlated with the
resistance of AD cells to serum deprivation-inducedapoptosis [36]. CaM thus seems to play a pivotal role
in transmitting proliferative/survival signals from the
plasma membrane to the nucleus. Whether CaM con-
tributes to cell proliferation or apoptosis depends on
cellular CaM levels as well as the presence of growth-
stimulatory signals. To our knowledge, there is very
little information about CaM levels in AD brain; how-
ever, impaired CaM-dependent activation of CaMKII
Figure 4 Calmodulin content in freshly isolated peripheral
blood mononuclear cells from control, mild cognitive
impairment and Alzheimer’s disease patients. Peripheral blood
mononuclear cells were isolated from freshly obtained blood from
15 control individuals, seven mild cognitive impairment (MCI)
patients and 21 Alzheimer’s disease (AD) patients (Table 1, lower
part) following density gradient centrifugation as described in
Methods. Cells were washed twice in phosphate-buffered saline,
lysed in ice-cold lysis buffer and subjected to immunoblot. A repre-
sentative experiment is shown. Band intensity was measured and
normalized by that of β-actin. To compare the results between ex-
periments, the same standard sample (ST) was included in every
western blot, and all values were referred to ST CaM levels. At
least two different experiments were performed with each indi-
vidual. Box plots represent CaM content in lymphoblasts from
healthy, MCI and AD patients. (*p <0.05, **p <0.01 significantly
different from control).
Figure 5 Calmodulin levels in plasma from control and
Alzheimer’s disease patients. Box plots represent the calmodulin
(CaM) concentration in plasma samples from healthy controls and
Alzheimer’s disease (AD) patients. Plasma was obtained after blood
centrifugation from six control individuals and six AD patients, and
CaM levels were measured by enzyme-linked immunosorbent assay.
(p = 0.09, two-tailed, unpaired Student’s t test).
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scribed in AD brain [47,48], and therefore it is tempt-
ing to speculate that changes in CaM levels in AD
lymphoblasts may be another peripheral sign of the
disease. Altered CaM levels in AD brain could play a
role in the cell cycle disturbance-induced neuronal
apoptosis.
In summary, our study reveals significant changes in
CaM levels in peripheral cells from AD patients and
MCI individuals. Our findings indicate that peripheral cell
CaM content has potential diagnostic power, differentiatingAD from other types of dementia, as well as from other
neurodegenerative disorders. Nevertheless, further work
with larger and independent populations of patients will be
needed before altered CaM content can be considered a
suitable biomarker for AD diagnosis.
Conclusion
CaM levels measured in peripheral cells could be con-
sidered a useful biomarker to help in early diagnosis of
AD, enabling one to discriminate AD from other demen-
tias with high levels of sensitivity and specificity.
Note: This article is part of a series on Peripheral Biomarkers,
edited by Douglas Galasko. Other articles in this series can be
found at http://alzres.com/series/biomarkers.
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